Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | DAO | P14920 | 2/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6564705 | 0.89 | TRPV4 (0.55) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| Hydrochloric Acid SCHEMBL28803020 | 0.87 | TRPV4 (0.53) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| SCHEMBL4825303 | 0.84 | TRPV4 (0.50) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| SCHEMBL11963202 | 0.84 | TRPV4 (0.50) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| SCHEMBL6411198 | 0.84 | TRPV4 (0.50) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| SCHEMBL3158141 | 0.83 | TRPV4 (0.57) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| SCHEMBL9240972 | 0.83 | HSD17B10 (0.49) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| Hydrochloric Acid SCHEMBL21798388 | 0.81 | TRPV4 (0.55) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| Hydrochloric Acid SCHEMBL6778748 | 0.81 | TRPV4 (0.55) | TRPV4DAOKCNJ1KCNH2CYP11B1 | |
| SCHEMBL4821602 | 0.80 | TRPV4 (0.46) | TRPV4DAOKCNJ1KCNH2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | TRPV4 869/4885DAO 966/4885KCNJ1 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.